Purine-Alkylator Combination In Follicular lymphoma Immuno-Chemotherapy for Older patients
ISRCTN | ISRCTN99217456 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN99217456 |
EudraCT/CTIS number | 2008-004759-31 |
ClinicalTrials.gov number | NCT01303887 |
Secondary identifying numbers | N/A |
- Submission date
- 22/01/2009
- Registration date
- 03/03/2009
- Last edited
- 20/03/2020
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Contact information
Prof Andrew Pettitt
Scientific
Scientific
University of Liverpool School of Cancer Studies
Division of Haematology
Level 2 Duncan Building
Royal Liverpool University Hospital
Daulby Street
Liverpool
L69 3GA
United Kingdom
Phone | +44 (0)151 706 4363 |
---|---|
arp@liv.ac.uk |
Study information
Study design | Phase III randomised controlled trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Hospital |
Study type | Treatment |
Participant information sheet | Not available in web format, please use the contact details to request a patient information sheet |
Scientific title | Purine-alkylator combination in follicular lymphoma immuno-chemotherapy for older patients: a phase III randomised controlled trial |
Study acronym | PACIFICO |
Study objectives | To investigate if the new immuno-chemotherapy combination regimen rituximab, fludarabine and cyclophosphamide (R-FC) improves rate of progression-free survival in older patients (aged 60+ years) when compared to the current gold standard treatment of rituximab, cyclophosphamide, vincristine and prednisone (R-CVP), without being significantly more toxic. Patients aged less than 60 years will be considered for the trial if more intensive chemotherapy is considered inappropriate due to co-morbidity. |
Ethics approval(s) | Added 09/03/2010: 1. Liverpool Adult Research Ethics Committee (MREC), 19/06/2009, ref: 09/H1005/29 2. Medicines and Healthcare products Regulatory Agency (MHRA), 03/07/2009, ref: 04196/0014/001-0001 |
Health condition(s) or problem(s) studied | Follicular lymphoma |
Intervention | Control arm (R-CVP): Rituximab 375 mg/m^2 intravenous (IV) day 1, cyclophosphamide 750 mg/m^2 IV day 1, vincristine 1.4 mg/m^2 IV day 1, prednisolone 40 mg/m^2 orally (PO) day 1 - 5, repeated every 21 days for 8 cycles. Experimental arm (R-FC): Rituximab 375 mg/m^2 IV day 1, fludarabine 40 mg/m^2 PO day 1 - 3, cyclophosphamide 250 mg/m^2 PO day 1 - 3, repeated every 21 days for 4 cycles followed by rituximab 375 mg/m^2 alone for 4 further cycles. Rituximab maintenance: All patients who have achieved a complete response (CR) or partial response (PR) to induction therapy will receive rituximab maintenance (375 mg/m^2 every 2 months for 2 years). |
Intervention type | Drug |
Pharmaceutical study type(s) | |
Phase | Phase III |
Drug / device / biological / vaccine name(s) | Rituximab, fludarabine, cyclophosphamide, vincristine, prednisone |
Primary outcome measure | 1. Progression free survival (PFS): length of PFS defined as number of days between date of randomisation and the date of progression, date of death from any cause or the date last seen progression free (censor date) 2. Toxicity: grade 3 - 4 infection will be used as the toxicity end-point. Toxicity will be measured according to standard National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 following each cycle of treatment and at each subsequent follow-up visit. |
Secondary outcome measures | 1. Response rates (overall, complete and partial) following initial therapy - assessment made following initial therapy 2. Response rates following maintenance therapy - assessment made following maintenance therapy 3. Response duration - time to event outcome 4. Overall survival - time to event outcome 5. Time to treatment failure - time to event outcome 6. Time-to-next treatment - time to event outcome 7. Number of treatment cycles delivered - assessment made following second-line therapy 8. Cumulative dose of individual drugs administered - assessment made following initial therapy 9. Quality of life - EORTC QLQ C-30, EQ-5D and EQ-VAS questionnaires will be completed at various time points during the course of treatment and follow up 10. Cost effectiveness - will be assessed at various time points during the course of treatment and follow up 11. Response to second-line therapy - assessment made following second-line therapy |
Overall study start date | 01/05/2009 |
Completion date | 01/07/2019 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Senior |
Sex | Both |
Target number of participants | 680 |
Key inclusion criteria | 1. Histologically confirmed follicular lymphoma, grade 1, 2, and 3a with material available for central review 2. Ann Arbor stage II - IV, i.e. all patients except those with strictly localised disease for whom local radiotherapy would be appropriate. Lymph nodes should be considered pathologically enlarged if the long axis is more than 1.5 cm regardless of the short axis. If a lymph node has a long axis of 1.1 to 1.5 cm, it should only be considered abnormal if its short axis is more than 1.0 cm. 3. Aged 60 years or over (or less than 60 but more intensive chemotherapy considered inappropriate due to co-morbidity), either sex 4. At least one of the following British National Lymphoma Investigation (BNLI) criteria for initiation of treatment: 4.1. Rapid generalised disease progression in the preceding 3 months 4.2. Life threatening organ involvement 4.3. Renal of macroscopic liver infiltration 4.4. Bone lesions 4.5. Presence of systemic symptoms or pruritus 4.6. Haemoglobin less than 10 g/dL or whole blood cell count (WBC) less than 3.0 × 10^9/L or platelet count less than 100 × 10^9/L due to marrow involvement 5. Adequate haematological function (unless abnormalities are related to lymphoma infiltration of the bone marrow) within 28 days prior to registration: 5.1. Haemoglobin greater than or equal to 8.0 g/dL 5.2. Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/L 5.3. Platelet count greater than or equal to 100 x 10^9/L 6. Written informed consent |
Key exclusion criteria | 1. Prior anti-lymphoma treatment 2. Overt transformation to diffuse large B-cell lymphoma 3. World Health Organization (WHO) performance status 3 or 4 4. Creatinine clearance less than 30 ml/min 5. Serum bilirubin more than twice upper limit of normal (unless due to lymphoma) 6. Life expectancy less than 12 months 7. Infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C. Patients with any serological evidence of current or past exposure to HIV, hepatitis B or hepatitis C are excluded unless the serological findings are clearly due to vaccination. 8. Allergy to murine proteins 9. Grade 3b follicular lymphoma 10. Presence or history of CNS disease (either CNS lymphoma or lymphomatous meningitis) 11. Patients regularly taking corticosteroids during the last 4 weeks, unless administered at a dose equivalent to less than 20 mg/day prednisolone 12. Patients with prior or concomitant malignancies except non-melanoma skin cancer or adequately treated in situ cervical cancer 13. Major surgery (excluding lymph node biopsy) within 28 days prior to registration 14. Serious underlying medical conditions, which could impair the ability of the patient to participate in the trial (e.g. ongoing infection, uncontrolled diabetes mellitus, gastric ulcers, active autoimmune disease) 15. Treatment within a clinical trial within 30 days prior to trial entry 16. Any other co-existing medical or psychological condition that will preclude participation in the study or compromise ability to give informed consent 17. Adult patient under tutelage (not competent to sign informed consent) |
Date of first enrolment | 01/05/2009 |
Date of final enrolment | 01/05/2017 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
University of Liverpool School of Cancer Studies
Liverpool
L69 3GA
United Kingdom
L69 3GA
United Kingdom
Sponsor information
University of Liverpool (UK)
University/education
University/education
Research and Business Services
The Foresight Centre
3 Brownlow Street
Liverpool
L69 3GL
England
United Kingdom
Website | http://www.liv.ac.uk/ |
---|---|
https://ror.org/04xs57h96 |
Funders
Funder type
Charity
Cancer Research UK (CRUK) (UK) (ref: C18029/A10015)
Private sector organisation / Other non-profit organizations
Private sector organisation / Other non-profit organizations
- Alternative name(s)
- CR_UK, Cancer Research UK - London, CRUK
- Location
- United Kingdom
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
HRA research summary | 28/06/2023 | No | No |
Editorial Notes
20/03/2020: EudraCT number added.
10/10/2018: The overall trial end date was changed from 01/05/2017 to 01/07/2019.
09/03/2010: The ethics approval details for this trial were added. This information can be found in the ethics approval field.